Anacor Pharmaceuticals enters antibiotic development agreement with DTRA

Anacor Pharmaceuticals announced on Monday that it has entered a research agreement with the Defense Threat Reduction Agency, a subsidiary of the U.S. Department of Defense, for the development of new systemic antibiotics.

The research agreement is between Anacor, the University of California at Berkeley and Colorado State University. The entities will work together during the next three and a half years to conduct research towards the discovery and development of systemic antibiotics to counter biological threats.

The research will be funded by DTRA's R&D Innovation and Systems Engineering Office through an award valued at $13.5 million. The Office was established to fund innovative technologies and strategies to combat weapons of mass destruction.

"Increasing resistance to existing antibiotics has created a critical need for new classes of antibiotics," Anacor CEO David Perry said. "We are pleased that DTRA recognizes the potential of Anacor's innovative boron chemistry, and we are looking forward to collaborating with DTRA, C.S.U. and U.C. Berkeley on this important research."

Under the agreement, Anacor will use its boron chemistry knowledge to design and discover novel antibiotics to counter a list of priority pathogens determined by DTRA. The agreement is part of DTRA's mission to continually improve countermeasures against viral and biological threats.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.